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Cancer-Specific Mortality among Korean Men with Localized or 
Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus




Studies comparing radical prostatectomy (RP) outcomes with those of radiotherapy with or
without androgen deprivation therapy (RT±ADT) for prostate cancer (PCa) have yielded con-
flicting results. Therefore, we used propensity score-matched analysis and competing risk
regression analysis to compare cancer-specific mortality (CSM) and other-cause mortality
(OCM) between these two treatments.
Materials and Methods
The multi-center, Severance Urological Oncology Group registry was utilized to identify 3,028
patients with clinically localized or locally advanced PCa treated by RP (n=2,521) or RT±ADT
(n=507) between 2000 and 2016. RT±ADT cases (n=339) were matched with an equal
number of RP cases by propensity scoring based on age, preoperative prostate-specific anti-
gen, clinical tumor stage, biopsy Gleason score, and Charlson Comorbidity Index (CCI). CSM
and OCM were co-primary endpoints.
Results
Median follow-up was 65.0 months. Five-year overall survival rates for patients treated with
RP and RT±ADT were 94.7% and 92.0%, respectively (p=0.105). Cumulative incidence 
estimates revealed comparable CSM rates following both treatments within all National
Comprehensive Cancer Network risk groups. Gleason score ! 8 was associated with higher
risk of CSM (p=0.009). OCM rates were comparable between both groups in the low- and
intermediate-risk categories (p=0.354 and p=0.643, respectively). For high-risk patients,
RT±ADT resulted in higher OCM rates than RP (p=0.011). Predictors of OCM were age ! 75
years (p=0.002) and CCI ! 2 (p < 0.001). 
Conclusion
RP and RT±ADT provide comparable CSM outcomes in patients with localized or locally 
advanced PCa. The risk of OCM may be higher for older high-risk patients with significant
comorbidities.
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Introduction
The management of clinically localized and locally 
advanced prostate cancer (PCa) is controversial. Contempo-
rary guidelines recommend that treatment decisions should
be made on the basis of tumor features, baseline prostate-
specific antigen (PSA) levels, patient age, comorbidity, life
expectancy, and quality of life [1,2]. In general, radical
prostatectomy (RP) and radiation therapy with or without
androgen deprivation therapy (RT±ADT) are viable treat-
ment options for patients with a life expectancy of more than
10 years [2].
Several studies have investigated the oncological outcomes
of RP and RT±ADT in order to identify the population that
would most benefit from a specific treatment and to deter-
mine which treatment is superior in terms of improving the
length or quality of life [3-8]. However, most of these studies
were retrospective in nature, and were limited by method-
ological biases arising from differences in pretreatment 
patient and cancer risk features between treatment cohorts
[9,10]. Therefore, their results were inconclusive and yielded
only weak evidence regarding which treatment was superior
in terms of oncological outcome.
A randomized controlled trial is the ideal approach for
comparing competing treatment modalities [11,12]. How-
ever, treatment options for PCa vary and decisions are
largely based on patient preference and physicians’ discre-
tion. Compared to candidates for RP, patients who are 
offered RT generally tend to be older, have higher comorbid-
ity scores, and have cancer-related risk features that are more
aggressive, making a randomized trial impractical [9,13]. For
instance, two large United States randomized trials compar-
ing RP and RT were closed early because of poor accrual [14].
A feasible alternative is a propensity-score matched analysis,
in which the possibility of patient selection bias can be min-
imized by adjusting for multiple preoperative confounders
that may affect survival outcome, such as patient age, disease
risk, and comorbidity [15]. The long lifespan of patients with
subclinical PCa presents another hurdle in addressing the 
effect of a specific treatment on clinically relevant endpoints
that truly represent the effect of a specific treatment, such as
cancer-specific mortality (CSM) and other-cause mortality
(OCM). Herein, a competing risks regression analysis can be
used to better understand the magnitude and timeline in
which a specific treatment might be expected to improve
these survival endpoints.
To address these issues, we performed a propensity score-
matched analysis followed by competing risk regression
analyses to compare CSM and OCM outcomes between RP
and RT±ADT in a multi-center cohort of Korean patients
with localized or locally advanced PCa. We further stratified
our analyses according to the National Comprehensive Can-
cer Network (NCCN) PCa risk category so that our results
could aid clinical decision making. 
Materials and Methods
1. Study population and data collection
A total of 3,082 consecutive Korean patients with localized
or locally advanced PCa treated with curative intent were 
selected from the multi-center, Severance Urological Oncol-
ogy Group PCa registry. Of these, 2,521 patients (81.8%) 
underwent RP and 561 patients (18.2%) received RT±ADT
between 2000 and 2016. The decision to use RP or RT±ADT
for treatment was based on surgeons’ discretion and on 
patients’ preference. Ninety-four patients (3.0%) with incom-
plete clinical information, 201 patients (6.5%) who were lost
to follow-up, and 107 patients (3.5%) for both reasons were
excluded from propensity-score calculation. This study was
approved by the institutional ethics committee after review
of the protocol and procedures employed (2014-0091-004).
2. Radical prostatectomy
RP was recommended for patients who either desired sur-
gical treatment or were determined to be reasonable surgical
candidates because of otherwise favorable clinical character-
istics. Surgery was performed by the retropubic or robotic
approach, with the extent of pelvic lymph node dissection
being based upon the risk category of the patient.
3. Radiation therapy
Radio-oncologists of each participating institution con-
firmed that conventional or hypo-fractionated external beam
RT was delivered to the prostate with pre-defined margins
according to the guidelines of the European Organization for
Research and Treatment of Cancer [16]. At Gangnam and
Shinchon Severance Hospitals, RT consisted of 3D conformal
radiation therapy (3DCRT) from 2000 to 2007 and intensity
modulated external beam RT (IMRT) from 2007 to 2016. The
median RT dose at Severance Hospitals was 7,000 cGy 
(interquartile range [IQR], 7,000 to 7,000 cGy). At Hallym
University College Hospital, RT consisted of 3DCRT from
2000 to 2001 and IMRT from 2001 to 2016. The median RT
dose at Hallym University College Hospital was 8,000 cGy
(IQR, 8,000 to 8,000 cGy). At Ajou University Hospital, RT
consisted of 3DCRT from 2000 to 2009 and IMRT from 2009
to 2016. The median RT dose at Ajou University Hospital was
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7,400 cGy (IQR, 7,010 to 7,400 cGy). The complete conversion
from 3DCRT to IMRT at all participating institutions took
place in 2011 along with the National Health Insurance Serv-
ice reimbursement coverage. In overall, 216 (63.7%) and 123
(36.3%) patients received of 3DCRT and IMRT, respectively.
The median total radiation dose was 70 Gy (IQR, 70 to 74 Gy)
in 33.5 fractions (IQR, 28 to 37 fractions), in which 295 
patients (87.0%) received greater than 7,600 cGy.
Pelvic lymph nodes were included if the patient had 
regional lymphadenopathies. Neoadjuvant, concomitant,
and/or adjuvant ADT was performed in 13/22 (59.1%),
69/108 (63.9%), and 186/209 (88.9%) of low-, intermediate-,
and high-risk patients, respectively.
4. Study endpoints
CSM and OCM were the co-primary endpoints. For all 
patients, the status of survival and cause of death were 
investigated using institutional electronic medical records,
the National Cancer Registry Database, or the Social Security
Death Index. Death was attributed to PCa if evidence of pro-
gressive metastatic castration-resistant PCa (CRPC) was
present, PCa was listed on the death certificate as the cause
of death, or if the patient died of complications of PCa treat-
ment. Secondary endpoints were biochemical recurrence-free
survival (BCRFS), adjuvant therapy following recurrence,
metastasis-free survival, and progression to CRPC-free sur-
vival. All patients received standard care according to con-
temporary guidelines until death or last follow-up.
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Table 1. Clinicopathological characteristics of patients, by initial treatment modality
Characteristic RP (n=339) RT±ADT (n=339) p-value
Propensity matched variable
Age (yr) 70.0 (66.0-73.0) 70.1 (66.0-74.0) 0.629
PSA (ng/mL) 10.4 (6.7-20.7) 10.7 (7.0-21.5) 0.814
Biopsy Gleason score (%)
! 6 78 (23.0) 78 (23.0) > 0.99 
7 133 (39.2) 133 (39.2)
8-9 128 (37.8) 128 (37.8)
Clinical T stage (%)
cT1 79 (23.3) 79 (23.3) > 0.99
cT2 140 (41.3) 140 (41.3)
cT3 99 (29.2) 99 (29.2)
cT4 21 (6.2) 21 (6.2)
CCI
0 224 (66.1) 224 (66.1) > 0.99
1 82 (24.2) 82 (24.2)
" 2 33 (9.7) 33 (9.7)
Unmatched variable
Clinical N stage (%)
N0 322 (95.0) 322 (95.0) > 0.99
N1 17 (5.0) 17 (5.0)
Clinical M stage (%)
M0 339 (100) 339 (100) NS
M1 0 ( 0 (
Body mass index (kg/m2) 23.7 (22.3-25.5) 23.6 (21.7-25.6) 0.948
NCCN risk criteria
Low 23 (6.8) 22 (6.5) 0.985
Intermediate 107 (31.9) 108 (32.2)
High 209 (61.3) 209 (61.3)
Total follow-up period (mo) 69.0 (42.7-94.0) 60.5 (39.0-98.0) 0.789
Values are presented as median (interquartile range) and number (%). RP, radical prostatectomy; RT±ADT, radiotherapy with
or without androgen deprivation therapy; PSA, prostate-specific antigen; CCI, Charlson comorbidity index; NS, not significant;
NCCN, National Comprehensive Cancer Network.
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Table 2. Causes of death and 5-year survival rates stratified by risk category and initial treatment modality
Variable RP (n=339) RT±ADT (n=339) p-value
Deaths, n (%) 29 (8.6) 46 (13.6) 0.038
PCa 6 (1.7) 4 (1.2) 0.530
Other cause 23 (6.8) 42 (12.4) 0.013
Second primary malignancy 7 (2.1) 13 (3.8) 0.758
Cardiopulmonary disease 3 (0.9) 7 (2.1) 0.645
Unknown 13 (3.8) 22 (6.5) 0.532
5-Year survival rate (%)
Cancer-specific 98.8 ( 99.5 ( 0.576
Low risk 100 ( 100 ( NS
Intermediate risk 100 ( 100 ( 0.994
High risk 98 ( 99.2 ( 0.399
Other-cause 95.3 ( 93.0 ( 0.051
Low risk 100 ( 100 ( NS
Intermediate risk 94.2 ( 90.5 ( 0.863
High risk 95.2 ( 92.9 ( 0.011
Overall 94.7 ( 92.0 ( 0.105
Low risk 100 ( 100 ( NS
Intermediate risk 94.2 ( 90.5 ( 0.871 
High risk 93.3 ( 92.1 ( 0.047
RP, radical prostatectomy; RT±ADT, radiotherapy with or without androgen deprivation therapy; PCa, prostate cancer; NS,
not significant.
Table 3. Oncological outcomes, by initial treatment modality
Variable RP (n=339) RT±ADT (n=339) p-value
BCR
No. (%) 108 (31.9) 57 (16.8) < 0.001
Time to BCR (mo) 17.0 (7.0-34.5) 40.0 (15.0-57.5) < 0.001
5-Year BCRFS (%) 3.7 ( 22.8 ( < 0.001
Adjuvant therapy following BCR
Observation 16 (4.7) 11 (3.2) 0.103
Salvage RT 18 (5.3) 2 (0.6)
ADT 44 (13.0) 40 (11.8)
Salvage RT plus ADT 30 (8.8) 4 (1.2)
CRPC (%)
No. (%) 16 (4.7) 14 (4.1) 0.721
Time to CRPC progression (mo) 35.5 (22.5-56.8) 60.5 (52.3-70.3) 0.013
CRPC progression-free survival (%) 18.8 ( 42.9 ( 0.071
Chemotherapy 7 (2.1) 9 (2.7) 0.603
Metastasis
No. (%) 12 (3.5) 12 (3.5) > 0.99
Time to metastasis (mo) 45.0 (26.0-71.3) 54.5 (24.5-68.0) 0.839
Metastasis-free survival rate (%) 33.3 ( 41.7 ( 0.778
Values are presented as number (%) or median (interquartile range), unless otherwise indicated. RP, radical prostatectomy;
RT±ADT, radiotherapy with or without androgen deprivation therapy; BCR, biochemical recurrence; BCRFS, BCR-free sur-
vival; CRPC, castration-resistant prostate cancer.
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5. Statistical analysis
The chi-square test and ANOVA were used to compare
two or more variables, and the Mann-Whitney U test was
used for the analysis of continuous variables. To address 
imbalances in the distribution of covariates among treatment
groups, we calculated propensity scores for each subject by
using multivariable logistic regression based on patient age,
preoperative PSA, biopsy Gleason score, clinical tumor stage,
and Charlson Comorbidity Index (CCI). Fine and Gray com-
peting risk regression analysis was used to evaluate the 
association of clinical covariates with CSM and OCM. Sur-
vival endpoints were estimated and compared using the 
Kaplan-Meier method and a log-rank test. Statistical analyses
were performed using R ver. 3.0.1 (R Foundation for Statis-
tical Computing, Vienna, Austria). All tests were two-sided,
with a statistical significance set at p < 0.05.
Results
1. Patient characteristics
Propensity matching yielded 339 RT±ADT cases matched
to an equal number of RP cases. Clinicopathological charac-
teristics of the two groups for matched and unmatched vari-
ables are presented in Table 1. Variables used for propensity-
score matching did not differ significantly between the two
groups; this finding was confirmed by the comparable distri-
bution of the NCCN risk criteria subgroups between the two
groups. The median follow-up period of the overall cohort
was 65.0 months (IQR, 40.0 to 95.0 months), with no significant
differences between the two treatment groups (p=0.789).
2. Causes of death
The causes of death according to treatment modality are
presented in Table 2. The causes of death were attributed to
PCa and other causes in 10/678 (1.5%) and 65/678 (9.6%) 
patients, respectively. The overall mortality (OM) rate in the
RT±ADT group was significantly higher than that in the RP
group (13.6% vs. 8.6%, p=0.038) because of a higher rate of
OCM in the RT±ADT group (p=0.013). The most common
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Univariate                                                                 MultivariateVariable
HR (95% CI) p-value HR (95% CI) p-value
Age (yr)
< 70 1 (reference) -
" 70 0.288 (0.060-1.391) 0.121 - -
Body mass index 0.953 (0.753-1.206) 0.687 - -
Pretreatment PSA 1.012 (0.973-1.054) 0.545 - -
Biopsy Gleason score
! 7 1 (reference) 1 (reference)
" 8 7.974 (1.649-38.56) 0.010 8.107 (1.676-39.21) 0.009
Clinical T stage
! T2 1 (reference) -
" T3 1.311 (0.323-5.316) 0.704 - -
CCI 
! 1 1 (reference) -
" 2 2.688 (0.719-10.05) 0.142 - -
Initial treatment modality
RP 1 (reference) -
RT±ADT 0.686 (0.182-2.588) 0.578 - -
Table 4. Pretreatment predictors of cancer-specific mortality in patients with clinically localized or locally advanced prostate
cancer
HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen; CCI, Charlson comorbidity index; RP, radical prosta-
tectomy; RT±ADT, radiotherapy with or without androgen deprivation therapy.
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cause of OCM was second primary malignancy, followed by
cardiopulmonary disease.
3. Survival outcome
Cumulative incidence estimates of CSM and OCM accord-
ing to treatment modality are presented in Table 2. Both treat-
ments resulted in comparable CSM in all NCCN risk groups
(p=0.576). However, the OCM rate in the RT±ADT group was
marginally higher than that in the RP group (p=0.051). This
could be attributed to a significantly higher rate of OCM in
high-risk patients who received RT±ADT (p=0.011). Accord-
ingly, a higher rate of OM was observed in high-risk patients
in the RT±ADT group (p=0.047).
Outcomes of secondary study endpoints are described in
Table 3. Patients who received RT±ADT had higher BCRFS
rates than those who underwent RP (p < 0.001). However, this
did not translate into superior oncological outcomes in terms
of rates of adjuvant therapy, CRPC progression-free survival,
or metastasis-free survival.
4. Predictors of cancer-specific mortality and OCM
A multivariate competing risks regression model was used
to identify pretreatment predictors of CSM and OCM. Gleason
score " 8 was significantly associated with a higher risk of
CSM (Table 4). Age " 75 years and CCI " 2 were independent
predictors of a higher risk of OCM (Table 5).
Discussion
Our results compare favorably with those of two random-
ized trials reported in the literature, which compared sur-
vival outcomes of RP with those of RT [17,18]. Akakura et al.
[17] reported no significant differences in CSM or overall sur-
vival according to treatment modality in patients with T2b-
3N0M0 PCa. The recently published ProtecT study also
revealed no difference in CSM between the RP and RT
groups [18]. However, the limitation of this study was that
men who received RP were younger and had lower PSA
compared to the RT group. Moreover, CCI was not accoun-
ted for. In contrast, several observational studies have 
reported that OM, CSM, and/or metastatic progression 
associated with RP are better than those associated with RT,
which contradicts the findings of the present study [5-8,
19,20]. Albertsen et al. [7] reported that the CSM associated
with RP was lower than that associated with RT during a 
Cancer Res Treat. 2018;50(1):129-137
Variable
Univariate                                                                 Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Age (yr)
< 70 1 (reference) 1 (reference)
" 70 1.684 (0.992-2.860) 0.053 1.894 (1.105-3.249) 0.020
Body mass index 0.895 (0.816-0.982) 0.019 0.924 (0.842-1.013) 0.091
Pretreatment PSA 1.010 (0.995-1.025) 0.207 - -
Biopsy Gleason score
! 7 1 (reference) -
" 8 0.976 (0.572-1.665) 0.929 - -
Clinical T stage
! T2 1 (reference) -
" T3 1.222 (0.718-2.078) 0.460 - -
CCI
! 1 1 (reference) 1 (reference)
" 2 2.837 (1.532-5.252) 0.001 2.853 (1.536-5.301) 0.001
Initial treatment modality
RP 1 (reference) 1 (reference)
RT±ADT 1.684 (0.992-2.860) 0.053 1.672 (0.978-2.858) 0.061
Table 5. Pretreatment predictors of other-cause mortality in patients with clinically localized or locally advanced prostate
cancer
HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen; CCI, Charlson comorbidity index; RP, radical prosta-
tectomy; RT±ADT, radiotherapy with or without androgen deprivation therapy.
134 CANCER  RESEARCH  AND  TREATMENT
Kyo Chul Koo, Radical Prostatectomy Versus Radiation Therapy
13-year follow-up. Although PCa risk and comorbidity were
adjusted for, their study did not reflect the current standard
of care because it was conducted during the early PSA era
[7]. Tewari et al. [19] used propensity risk scoring and 
reported that CSM and OM in patients with high grade PCa
treated with RP were lower than those in patients treated
with EBRT. Zelefsky et al. [6] and Merglen et al. [5] reported
that CSM in men treated with RT was higher than that in
men who underwent RP. However, patients treated with RT
tended to be older, with higher PSA and Gleason scores, pre-
cluding a meaningful comparison. Furthermore, no adjust-
ments were made for comorbidity [5,6]. The superiority of
RP observed in these studies may be attributed to the 
improved ability to interpret early post-treatment PSA
changes and to deliver timely and effective adjuvant therapy
by enabling a pathologic assessment of the primary tumor
[20]. Moreover, patients for whom RP was deemed appro-
priate may have been better screened for second primary 
malignancies or comorbidities such as cardiopulmonary dis-
ease, which contributes to OCM. Nevertheless, the most 
reliable quantitative exploratory analyses, including the
aforementioned observational studies, concluded that the
differences in 10-year CSM are less than 1%, and that the 
unadjusted survival curves and unaccounted-for confoun-
ders in these studies preclude a definitive conclusion that RP
results in superior survival compared to RT±ADT [21].
Patients treated with RT±ADT exhibited higher BCRFS
rates than those who underwent RP. However, this finding
did not translate into improvement in consequent oncologi-
cal outcomes during our observational period. The high rate
of ADT administration in our patients treated with RT may
have contributed to this result. Overall, 78% of the patients
who received RT in the current analysis also received neoad-
juvant, concomitant, and/or adjuvant ADT. This proportion
is markedly higher than the 51% to 56% reported in previous
studies [6]. This may be, in part, due to the higher proportion
of high-risk patients in our cohort who received ADT, a prac-
tice based on evidence that RT with ADT results in better sur-
vival than that for RT alone [2]. Indeed, the use of ADT in
the RT group is a potential confounding factor for compar-
isons between RP and RT. Nevertheless, we did not adjust
for the use of ADT in the present study for several reasons.
First, the use of ADT is associated with disease risk, such that
higher risk patients are more likely to receive ADT. The 
impact of ADT is usually reflected in the risk adjustment. In
previous studies using models adjusted for risk, ADT was
not proven to be an independent predictor [13,22]. Second,
BCRFS which may be affected by the use of ADT, was not
the primary endpoint of our study. Biochemical recurrence
is known to antedate clinical progression by a median of 5 to
7 years [23]. However, considering the protracted natural his-
tory of PCa, biochemical recurrence is an imprecise proxy for
CSM or OM.
A noteworthy finding in the present study was that the
OCM rate in patients who received RT±ADT was higher than
that in patients who underwent RP. Although propensity-
score matching was utilized to adjust for confounding 
comorbidities that might have increased OCM, unobserved
and unaccounted disparities between the groups may have
existed. CCI has been suggested to predict the risk of OCM
unreliably, and adequate adjustments are best applied when
populations are more homogeneous, such as those with a
CCI of 0 [8,21]. To account for this issue, we compared sur-
vival outcomes within patients with a CCI of 0. Interestingly,
no differences in OCM were observed within this subgroup
(data not shown). This observation implies that CCI may fail
to ensure adequate adjustments for OCM in patients with at
least one or more significant comorbidity. The administration
of ADT is another potential risk factor contributing to car-
diopulmonary disease as the cause of OCM. Studies have
suggested increased risk of cardiopulmonary disease with
long term ADT [24,25]. However at the same time, there
equal levels of evidences that oppose this observation [26,27].
The jury is still out whether lower levels of testosterone has
caused more cardiopulmonary disease and have contributed
to higher OCM rates in our patients who received RT+ADT.
The present study has a few noteworthy limitations. (1) 
Although we utilized a propensity-score matched analysis,
unobserved and unaccounted disparities between cohorts
may have existed, as evidenced by our subset analysis of 
patients without any comorbidities. (2) The aim of our study
was to provide a guide to aid clinical decision making at 
diagnosis. Thus, no adjustments were made for confounders
that may contribute to survival following initial treatment,
namely, salvage therapy, duration of ADT, or administration
of chemotherapy or androgen receptor-targeted therapy. 
Although studies comparing RP and RT have reported that
adjustment for salvage therapy had no impact on survival
outcomes [6], it is difficult to preclude the effect of salvage
therapy considering multidisciplinary treatment strategies
and the prolonged natural history of PCa. (3) Treatments are
constantly evolving and advances in radiation delivery may
have some impact of survival. Randomized trials have
demonstrated dose-escalated RTx (74-90 Gy) to improve
BCRFS compared to conventional RTx (64-70 Gy) [28]. How-
ever, we did not account for this confounder because none
have demonstrated improvement in CSM or OM with higher
doses or variations in technique, such as intensity modula-
tion [29,30]. Moreover, no differences in BCRFS or CSM were
noted according to radiation dose subgroups (data not
shown). (4) A limited number of cases of CSM occurred in
the low-risk group, which limited our ability to draw statis-
tically significant conclusions. (5) The follow-up period was
relatively short compared to previous similar studies. 
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Although higher BCRFS rates observed in patients treated
with RT±ADT did not translate into superior oncological
endpoints, a longer observational period would be needed
for a meaningful comparison of overall survival. (6) We did
not investigate the differences in adverse events and quality
of life, which are meaningful clinical endpoints.
RP and RT±ADT yield comparable CSM outcomes in 
Korean patients with localized or locally advanced PCa. Our
results imply that the risk of OCM may be higher for older
high-risk patients with significant comorbidities. Future 
investigations focusing on long-term cancer control as well
as functional and patient satisfaction outcomes will be nec-
essary for a more definitive conclusion.
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